Prometheus Biosciences Inc   (RXDX)
Other Ticker:  
Price: $199.9200 $0.18 0.090%
Day's High: $199.98 Week Perf: 0.47 %
Day's Low: $ 199.60 30 Day Perf: 3.84 %
Volume (M): 1,861 52 Wk High: $ 199.98
Volume (M$): $ 371,971 52 Wk Avg: $161.15
Open: $199.68 52 Wk Low: $104.55

 Market Capitalization (Millions $) 9,488
 Shares Outstanding (Millions) 47
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -151
 Cash Flow (TTM) (Millions $) -149
 Capital Exp. (TTM) (Millions $) 2

Prometheus Biosciences Inc
Prometheus Biosciences Inc is a biotechnology company focused on developing and commercializing precision therapeutics and companion diagnostics for immune-mediated diseases. The company's goal is to improve patient outcomes by providing personalized treatments that target the specific molecular and cellular mechanisms of these diseases. Prometheus Biosciences utilizes cutting-edge technologies and scientific expertise to identify and develop innovative therapies, with an emphasis on inflammatory bowel disease (IBD) and other autoimmune diseases. They work in collaboration with academic institutions, research organizations, and pharmaceutical companies to accelerate the discovery and development of precision medicines.

   Company Address: 3050 Science Park Road San Diego 92121 CA
   Company Phone Number: 422-4300   Stock Exchange / Ticker: NASDAQ RXDX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Prometheus Biosciences Inc

Prometheus Biosciences Inc Faces -71.804% Drop in Top-Line for 2023 Q3 Earnings Season: A Potential Investment Opportunity Amidst Industry Volatility

Despite the recent announcement of a disastrous January to March 31, 2023 financial report from Prometheus Biosciences Inc, there are still bullish indicators that suggest this is a company worth investing in.
First and foremost, it's important to acknowledge that the pharmaceutical industry is notorious for its volatility. Powerhouses of the industry such as Pfizer and Merck have seen their fair share of ups and downs. With that being said, the fact that Prometheus Biosciences Inc experienced a drop in revenue and an expansion of net deficit per share is not entirely unexpected. However, what is impressive is the fact that the company's revenue has surged by 69.219% from the previous reporting season and is still at $1.11 million despite the decline.


Prometheus Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com